These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11935218)

  • 1. Preclinical study of dolastatin-10 in dogs with spontaneous neoplasia.
    Thamm DH; MacEwen EG; Phillips BS; Hershey AE; Burgess KM; Pettit GR; Vail DM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):251-5. PubMed ID: 11935218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
    Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
    Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation.
    Thamm DH; Kurzman ID; King I; Li Z; Sznol M; Dubielzig RR; Vail DM; MacEwen EG
    Clin Cancer Res; 2005 Jul; 11(13):4827-34. PubMed ID: 16000580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors.
    Ebbinghaus S; Rubin E; Hersh E; Cranmer LD; Bonate PL; Fram RJ; Jekunen A; Weitman S; Hammond LA
    Clin Cancer Res; 2005 Nov; 11(21):7807-16. PubMed ID: 16278403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity of dolastatin 10 in mice, rats and dogs and its clinical relevance.
    Mirsalis JC; Schindler-Horvat J; Hill JR; Tomaszewski JE; Donohue SJ; Tyson CA
    Cancer Chemother Pharmacol; 1999; 44(5):395-402. PubMed ID: 10501913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical investigation of PEGylated tumor necrosis factor alpha in dogs with spontaneous tumors: phase I evaluation.
    Thamm DH; Kurzman ID; Clark MA; Ehrhart EJ; Kraft SL; Gustafson DL; Vail DM
    Clin Cancer Res; 2010 Mar; 16(5):1498-508. PubMed ID: 20160058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers.
    Rusk A; McKeegan E; Haviv F; Majest S; Henkin J; Khanna C
    Clin Cancer Res; 2006 Dec; 12(24):7444-55. PubMed ID: 17189418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
    Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
    Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
    Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE
    J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.
    Horti J; Juhasz E; Monostori Z; Maeda K; Eckhardt S; Bodrogi I
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):173-80. PubMed ID: 18214483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
    Cunningham C; Appleman LJ; Kirvan-Visovatti M; Ryan DP; Regan E; Vukelja S; Bonate PL; Ruvuna F; Fram RJ; Jekunen A; Weitman S; Hammond LA; Eder JP
    Clin Cancer Res; 2005 Nov; 11(21):7825-33. PubMed ID: 16278405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies.
    London CA; Hannah AL; Zadovoskaya R; Chien MB; Kollias-Baker C; Rosenberg M; Downing S; Post G; Boucher J; Shenoy N; Mendel DB; McMahon G; Cherrington JM
    Clin Cancer Res; 2003 Jul; 9(7):2755-68. PubMed ID: 12855656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
    de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
    Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
    Rademaker-Lakhai JM; Horenblas S; Meinhardt W; Stokvis E; de Reijke TM; Jimeno JM; Lopez-Lazaro L; Lopez Martin JA; Beijnen JH; Schellens JH
    Clin Cancer Res; 2005 Mar; 11(5):1854-62. PubMed ID: 15756010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhalation chemotherapy for macroscopic primary or metastatic lung tumors: proof of principle using dogs with spontaneously occurring tumors as a model.
    Hershey AE; Kurzman ID; Forrest LJ; Bohling CA; Stonerook M; Placke ME; Imondi AR; Vail DM
    Clin Cancer Res; 1999 Sep; 5(9):2653-9. PubMed ID: 10499645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.
    Dean E; Jodrell D; Connolly K; Danson S; Jolivet J; Durkin J; Morris S; Jowle D; Ward T; Cummings J; Dickinson G; Aarons L; Lacasse E; Robson L; Dive C; Ranson M
    J Clin Oncol; 2009 Apr; 27(10):1660-6. PubMed ID: 19237630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors.
    Vail DM; Kravis LD; Cooley AJ; Chun R; MacEwen EG
    Cancer Chemother Pharmacol; 1997; 39(5):410-6. PubMed ID: 9054954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
    Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
    Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy.
    Patel S; Keohan ML; Saif MW; Rushing D; Baez L; Feit K; DeJager R; Anderson S
    Cancer; 2006 Dec; 107(12):2881-7. PubMed ID: 17109446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.